LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

14.53 -5.95

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.53

Max

15.44

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.2M -12M
Werknemers	37
EBITDA	-2.1M -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+104.53% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	16M 1.3B
Vorige openingsprijs	20.48
Vorige sluitingsprijs	14.53

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 23:58 UTC

Winsten

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mei 2026, 22:57 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mei 2026, 23:52 UTC

Winsten

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mei 2026, 23:28 UTC

Marktinformatie

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mei 2026, 23:11 UTC

Winsten

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mei 2026, 23:06 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mei 2026, 23:05 UTC

Winsten

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mei 2026, 23:04 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mei 2026, 23:02 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mei 2026, 23:00 UTC

Marktinformatie

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mei 2026, 22:42 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mei 2026, 22:33 UTC

Winsten

Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mei 2026, 22:32 UTC

Winsten

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie: 68% of FY Income From International >MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mei 2026, 22:29 UTC

Winsten

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mei 2026, 22:26 UTC

Winsten

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mei 2026, 22:25 UTC

Winsten

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

104.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 104.53%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.